Role of Th1 and Th2 cells in neurologic disorders

Chemical Immunology

Volumn 63, Issue , 1996, Pages 171-186

  Windhagen, Anja ^a   Nicholson, Lindsay B ^a   Weiner, Howard L ^a   Kuchroo, Vijay K ^a   Hafler, David A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ALLERGIC ENCEPHALOMYELITIS; CEREBROSPINAL FLUID; HELPER CELL; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS; TH1 CELLS; TH2 CELLS;

EID: 0029916204     PISSN: 10150145     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Li H, Newcombe J, Cuzner JL: Characterization and distribution of phagocytic macrophages in MS plaques. Neuropathol Appl Neurobiol 1993;19:214-223.
2. Cuzner ML, Hayes GM, Newcombe J, Woodroofe MN. The nature of inflammatory components during demyelination in multiple sclerosis. J Neuroimmunol 1988;20.203-209
3. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA: T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990;346:183-187.
4. Zhang J, Medaer R, Chin Y, van den Berg-Loonen E, Raus JC. Myelin basic protein-specific T lymphocytes in multiple sclerosis and controls: Precursor frequency, fine specificity and cytotoxicity. Ann Neurol 1992;32:330-338.
5. Allegretta M, Nicklas JA, Sriam S, Albertini RJ: T cells responsive to myelin basic protein in patients with multiple sclerosis Science 1990;247:718.
6. Zhang J, Markovic S, Lacet B, Raus J, Weiner HL, Hafier DA: Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis J Exp Med 1994;179:973-984.
7. Mossmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clones. J Immunol 1986;136:2348-2357.
8. Romagnanì S: Lymphokine production by human T cells in disease states. Ann Rev Immunol 1994; 12:227-257.
9. Scott P: IL-12: Initiation cytokine for cell-mediated immunity. Science 1993;260:496-497.
10. Freeman GJ, Borriello F, Hodes RJ, Reiser H, Gribben JG, Ng JW, Kim J, Goldberg JM, Hathcock K, Laszlo G, Lombard LA, Wang S, Gray GS, Nadler LM, Sharpe AH: Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J Exp Med 1993;178.2185-2192.
11. Freeman G, Borriello F, Hodes RJ, Reiser H, Hathcock KS, Laszlo G, McKnight AJ, Kim JJ, Du L, Lombard DB, Gray GS, Nadler LM, Sharpe AH: Uncovering the functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 1993;262.907-909.
12. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA Jr, Lombard LA, Gray GS, Nadler LM Cloning of B7-2: CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993;262:909-911.
13. Harlan DM, Hengartner H, Huang ML, Kang Y, Abe R, Moreadith RW, Pircher H, Gray GS, Ohashi PS, Freeman GJ, Nadler LM, June CH, Aichelle P: Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness. Proc Natl Acad Sci USA 1994; 91:3137-3141.
14. Guerder S, Meyerhoff J, Flavell R: The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen Immunity 1994,1: 155-166.
15. Wekerle H: Experimental autoimmune encephalomyelitis as a model of immune-mediated CNS disease Curr Opin Neurobiol 1993;3:779-784.
16. Alvord EC Jr, Kies MW, Suckling AJ: Experimental Allergic Encephalomyelitis: A Useful Model for Multiple Sclerosis. New York, Liss, 1984.
17. Lafaille JJ, Nagashima K, Katsuki M, Tonegawa S: High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice. Cell 1994;78:399-408
18. Zamvil SS, Steinman L: The T lymphocyte in experimental allergic encephalomyelitis Annu Rev Immunol 1990;8.579-621.
19. Kuchroo VK, Sobel RA, Laning JC, Martin CA, Greenfield E, Dorf ME, Lees MB: Experimental allergic encephalomyelitis mediated by cloned T cells specific for a synthetic peptide of myelin proteolipid protein. J Immunol 1992;148:3776-3782.
20. Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, Grunnet ML, Padula SJ, Clark RB: An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis J Exp Med 1990;1723:1193-1200.
21. Chung IY, Norris JG, Benveniste EN: Differential tumour necrosis factor-α expression by astrocytes from experimental allergic encephalomyelitis-susceptible and -resistant rat strains. J Exp Med 1991; 173:801-811
22. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N: Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 1992;356: 63-66.
23. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA: Surface expression of α4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 1993;177:57-68.
24. Kuchroo VJ, Martin CA, Greer JM, Ju S, Sobel RA, Dorf ME: Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis. J Immunol 1993;151:4371-4382.
25. Khoury SJ, Hancock WW, Weiner HL: Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain J Exp Med 1992;176:1355-1364.
26. Kennedy MK, Torrance DS, Picha KS, Mohler KM: Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 1992;149:2496-2505
27. Weiner HL, Friedman A, Miller A, Khoury SJ, Al-Sabbagh A, Santos L, Sayegh M, Nussenblatt RB, Trentham DE, Hafler DA: Oral tolerance. Immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Ann Rev Immunol 1994;12:809-837.
28. McRae BL, Kennedy MK, Tan LJ, Dal Canto MC, Picha KS, Miller SD: Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J Neuroimmunol 1992;38:229-240.
29. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL: Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 1994;265:1237-1240.
30. Kuchroo VK, Prabhu Das M, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N, Glimcher LH: B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell 1995,80:707-718.
31. Paul WE, Seder RA: Lymphocyte responses and cytokines Cell 1994;76:241-251.
32. Shankar AH, Titus RG: T cell and non- T cell compartments can independently determine resistance to Leishmania major. J Exp Med 1995;181:845-855.
33. Kalman B, Knobler RL, Lublin FD: T cell receptor Vβ gene utilization in myelin basic protein specific clones from CXJ1 recombinant inbred mice. J Neuroimmunol 1993;43:191-194.
34. Janeway C, Carding S, Jones B, Murray J, Portoles P, Rasmussen R, Saizawa K, West J, Bottomly K: CD4+ T cells: Specificity and function. Immunol Rev 1988;101:39-80.
35. Weiner HL, Macklin GA, Matsui M, Orav EJ, Khoury SJ, Dawson DM, Hafler DA: Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis Science 1993;259:1321-1324.
36. Chen Y, Inobe J, Marks R, Gonnella P, Kuchroo VK, Weiner HL: Peripheral deletion of antigen-reactive T cells following oral tolerance. Nature 1995;376:177-180.
37. Kuchroo VK, Greer JM, Kaul D, Ishioka G, Franco A, Sette A, Sobel RA, Lees MB: A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J Immunol 1994;153:3326-3336.
38. Karin N, Mitchell DJ, Brocke S, Ling N, Steinman L: Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon-γ and tumor necrosis factor-α production. J Exp Med 1994; 180:2227-2237.
39. Pfeiffer C, Stein J, Southwood S, Ketelaar H, Sette A, Bottomly K: Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med 1995;181:1569-1574.
40. Franciotta DM, Grimaldi LME, Martino GV, Piccolo G, Bergamaschi R, Citteria A, Malzi d'Eril GV. TNF in serum and CSF of patients with multiple sclerosis Ann Neural 1989;26:787-789.
41. Perrella O, Carrieri PB, De Mercato R, Buscaino GA: Markers of activated T-lymphocytes and T-cell receptor gamma delta+ in patients with MS. Eur Neurol 1993;33 152-155.
42. Peter GB, Boctor FN, Tourtellotte WW: Serum and CSF levels of IL-2, sIL-2R, TNF-α and IL-1beta in chronic progressive multiple sclerosis: Expected lack of clinical utility. Neurology 1991;41: 121-123.
43. Konttinen YT, Kinnunen E, Kemppinen P, Juntunen J, Koskenvuo M: Lymphocyte activation in discordant multiple sclerosis twin pairs. J Neuroimmunol 1990,27.1-8.
44. Gallo P, Piccino MG, Krzalic L, Tavolato B: Tumor necrosis factor and neurological diseases: Failure in detecting TNF in the CSF from patients with multiple sclerosis. AIDS dementia complex and brain tumor. J Neuroimmunol 1989,23:41-44.
45. Sharief MK, Hentges R: Association between tumor necrosis factor alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991;325-467-472.
46. Tsukada N, Miyagi K, Matsuda M, Yanagisawa N, Yone K: Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J Neurol Sci 1991;102:230-234.
47. Maimone D, Gregory S, Arnason BGW, Redder AT: Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 1991;32:67-74
48. Sharief MK, McLean B, Thompson EJ: Elevated serum levels of tumor necrosis factor alpha in Guillain-Barre syndrome. Ann Neurol 1993;33:591-596.
49. Astroianni CM, Paoletti F, Valenti C, Vullo V, Jirillo E, Delia S. Tumor necrosis factor and neurological disorders in HIV infection. J Neurol Neurosurg Psychiatry 1992;55:219-221
50. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, Luer W, Poser S: Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 1994;44: 1523-1526.
51. Mokhtarian F, Shi Y, Shirazian D, Morgante L, Miller A, Grob D: Defective production of anti-inflammatory cytokine, TGF beta by T cell lines of patients with active multiple sclerosis. J Immunol 1994;152:6003-6010.
52. Rieckmann P, Albrecht M, Kitze B:, Weber T, Tumani H, Broocks A, Luer W, Helwig A, Poser S: Tumor necrosis factor a messenger RNA expression in patients with relapsing remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-88.
53. Zipp F, Weber F, Sorgiu S, Holler E, Weiss EH, Wekerle H, Hohlfeld R: Increased production of lymphotoxin and TNF-a by antigen-specific T cell lines from HLA-DR2 positive individuals: Implications for multiple sclerosis. 4th Meet Eur Neurol Soc, 1994.
54. Brod SA, Benjamin D, Hafler DA: Restricted T cell expression of IL-2/IFN-γ mRNA in human inflammatory disease. J Immunol 1991;147:810-815.
55. Olsson T: Cytokines in neuroinflammatory disease Role of myelin autoreactive T cell production of Interferon-gamma. J Neuroimmunol 1993;40:211-218.
56. Correale J, Gilmore W, McMillan M, Li S, McCarthy K, Le T, Weiner LP: Patterns of cytokine secretion by autoreactive proteolipid protein specific T cell clones during the course of multiple sclerosis. J Immunol 1995;154.2959-2968.
57. Windhagen A, Williams R, Carrizosa A, Hafler DA. Antigen stimulation in the presence of IL-12/ α-IL-4 mAb induces a T cell subset characterized by secretion of IL-10 and IFN-γ. 1995; submitted.
58. Inoue T, Asano Y, Matsuoka S, Furutani-Seiki M, Aizawa S, Nishimura H, Shirai T, Tada T: Distinction of mouse CD8+ suppressor effector cell clones from cytotoxic T cell clones by cytokine production and CD45 isoforms. J Immunol 1993;150:2121-2128.
59. Miller A, Lider O, Roberts A, Sporn MB, Weiner H: Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering Proc Natl Acad Sci USA 1992, 89:421-425.
60. Antel J, Bania M, Noronha A, Neely S: Defective suppressor cell function mediated by T8+ cell lines from patients with progressive multiple sclerosis. J Immunol 1986;137:3436-3439.
61. Antel JP, Bania MB, Reder A, Neil C: Activated suppressor cell dysfunction in progressive multiple sclerosis. J Immunol 1986;137:137-141.
62. Chofflon M, Weiner H, Morimoto C, Hafler DA: Loss of functional suppression is linked to decreases in circulating suppressor inducer (CD4+2H4+) T cells in multiple sclerosis. Ann Neurol 1988;24:185-191
63. Hafler DA, Buchsbaum M, Weiner H: Decreased autologous mixed lymphocyte reaction in multiple sclerosis J Neuroimmunol 1985;9:339-347.
64. Balashov K, Khoury S, Hafler D, Weiner H: Inhibition of T cell responses by activated human CD8+ T cells is mediated by IFN-γ and is defective in chronic progressive multiple sclerosis 1995; submitted.
65. Traugott U, Lebon P: Interferon gamma and Ia antigen are present on astrocytes in active chronic multiple sclerosis lesions. J Neurol Sci 1988;84:257-264
66. Hofman FM, Hinton DR, Johnson K, Merrill JE: Tumor necrosis factor identified in multiple sclerosis brain J Exp Med 1989;170:607-612.
67. Selmaj K, Raine CS, Cannella B, Brosnan CF: Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991;87:949-954.
68. Wesselingh SL, Power C, Glass J, Tyor WR, McArthur JC, Farber JM, Griffin JW, Griffin DE: Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia. Ann Neurol 1993;33:576-582.
69. Nagano I, Nakamura S, Yoshioka M, Onodera J, Kogure K, Itoyama Y: Expresssion of cytokines in brain lesions in subacute sclerosing panencephalitis. Neurology 1994;44:710-715.
70. Windhagen A, Newcombe J, Dangond F, Li H, Woodroofe N, Cuzner ML, Hafler DA: Expression of IL-12 and B7 costimulatory molecules in multiple sclerosis lesions. J Exp Med 1995; in press.
71. Woodroofe MN, Cuzner ML: Cytokine mRNA expression in inflammatory multiple sclerosis lesions: Detection by non-radioactive in situ hybridization. Cytokine 1993;5:583-588.
72. Tyor WR, Glass JD, Griffin JW, Becker PS, McArthur JC, Bezman L, Griffin DE: Cytokine expression in the brain during the acquired immunodeficiency syndrome Ann Neurol 1992;31: 349-360.
73. Panitch HS, Hirsch RL, Haley AA, Johnson KP: Exacerbations of multiple sclerosis in patients treated with γ-IFN. Lancet 1987;i:893.
74. Leonard JP, Waldburger KE, Goldman SJ: Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 1995;181:381-386.
75. Arnon R, Teitelbaum D: Immunomodulation of experimental allergic encephalomyelitis. Isr J Med Sci 1993;29:175-181.